Table 1 Baseline characteristics in patients with lupus nephritis (n = 103)
From: Value of monitoring urine ammonia at time of biopsy in patients with lupus nephritis
Clinical evaluation | Laboratory assessment | Renal histopathology indices (median, range) | |||
|---|---|---|---|---|---|
Female,n(%) | 86 (83.50) | WBC(10^9/L) | 4.73 (3.50,7.06) | AI scores | 4 (1,10) |
Age (years) | 39.75 ± 14.39 | Hb(g/L) | 100 (90,116) | Endocapillary hypercellularity | 0 (0,1) |
SLE duration (months) | 4 (1,24) | PLT(10^9/L) | 167.50 ± 67.34 | Cellular crescents | 0 (0,6) |
Hypertension,n (%) | 35 (33.98) | eGFR (ml/min/1.73 m2) | 86.76 (52.11,117.36) | Karyorrhexis/fibrinoid necrosis | 0 (0,2) |
Hematuria,n(%) | 54 (52.43) | Urine protein(g/24 h) | 2.94 (1.29,5.51) | Subendothelial hyaline deposits | 1 (0,2) |
Nephrotic syndrome,n(%) | 42 (40.78) | Cystatin C (mg/L) | 1.57 (1.09,2.35) | Interstitial inflammatory cell infiltration | 2 (1,3) |
SLEDAI-2 K | 11 (9,24) | SCr (umol/L) | 76.30 (53.70,116.20) | Glomerular leukocyte infiltration | 0 (0,1) |
rSLEDAI | 4 (4,8) | BUN (mmol/L) | 6.93 (4.67,11.10) | CI scores | 2 (0,11) |
SBP (mmHg) | 130 (122,143) | Uric acid (umol/L) | 407.14 ± 125.09 | Glomerular sclerosis | 1 (0,3) |
DBP (mmHg) | 85 (78,91) | Albumin(g/L) | 25.72 ± 7.39 | Fibrous crescents | 0 (0,3) |
| Â | Â | Anti-ANA antibodies (+), n (%) | 96 (93.20) | Tubular atrophy | 1 (0,3) |
| Â | Â | Anti-Sm antibodies(+), n (%) | 54 (52.43) | Interstitial fibrosis | 0 (0,3) |
| Â | Â | Anti-dsDNA antibodies(+), n (%) | 63 (61.17) | Â | Â |
| Â | Â | IgG(g/L) | 12.75 (7.56,16.15) | Â | Â |
| Â | Â | C3(g/L) | 0.49 (0.37,0.82) | Â | Â |
| Â | Â | C4(g/L) | 0.10 (0.07,0.17) | Â | Â |